Serum Levels of Bupivacaine in Autotransfusion Drains Following Total Joint Arthroplasty

• Status: Completed
• Trial end date: 2017-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to quantify the total blood serum levels of bupivacaine in OrthoPAT® collected blood 2 hours and 5 hours postoperatively.

Hypothesis: Filtered blood from the OrthoPAT® autotransfusion system contains low or undetectable levels of bupivacaine hydrochloride (HCL). Reinfusion of collected blood from the OrthoPAT® device when used in conjunction with periarticular bupivicaine injections will not pose a bupivocaine toxicity risk to patients undergoing a total joint arthroplasty.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OrthoCarolina Research Institute, Inc.
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• Patients undergoing primary total joint arthroplasty with use of periarticular bupivicaine and liposomal bupivicaine and OrthoPAT® auto reinfusion system.

• At least 18 years of age.

Exclusion Criteria:

• Allergy to bupivacaine.

• Allergy to epinephrine.

• Patients that are not presenting for a primary TJA

• Patients who are having a TJA without OrthoPAT® auto reinfusion system.

• Patients under age 18.